126 related articles for article (PubMed ID: 26355234)
1. BRAF-mutated metastatic colorectal cancer between past and future.
Cremolini C; Di Maio M; Petrelli F; Berenato R; Loupakis F; Pietrantonio F
Br J Cancer; 2015 Dec; 113(11):1634-5. PubMed ID: 26355234
[No Abstract] [Full Text] [Related]
2. Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.
Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
Br J Cancer; 2015 Dec; 113(11):1635. PubMed ID: 26355231
[No Abstract] [Full Text] [Related]
3. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
[No Abstract] [Full Text] [Related]
4. Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
Hess LM; Carter G; Smolen L; Bowman L; von Hohnhorst P; Seagle C
J Natl Cancer Inst; 2014 Feb; 106(2):djt370. PubMed ID: 24381069
[No Abstract] [Full Text] [Related]
5. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
6. KRAS genotypes and outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
Zaccarelli E; Tomao S; Codacci-Pisanelli G
JAMA; 2011 Feb; 305(6):565-6; author reply 566. PubMed ID: 21304079
[No Abstract] [Full Text] [Related]
7. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
8. How should BRAF V600E-mutated colorectal cancer be treated?
Kopetz S
Clin Adv Hematol Oncol; 2018 May; 16(5):333-335. PubMed ID: 29851929
[No Abstract] [Full Text] [Related]
9. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.
Modest DP; Jung A; Moosmann N; Laubender RP; Giessen C; Schulz C; Haas M; Neumann J; Boeck S; Kirchner T; Heinemann V; Stintzing S
Int J Cancer; 2012 Aug; 131(4):980-6. PubMed ID: 21960311
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
[TBL] [Abstract][Full Text] [Related]
11. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F
Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282
[TBL] [Abstract][Full Text] [Related]
12.
van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
[TBL] [Abstract][Full Text] [Related]
13. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
14. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
Abdel-Rahman O
Future Oncol; 2016 Jan; 12(1):25-30. PubMed ID: 26616508
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases.
Velho S; Oliveira C; Seruca R
J Clin Oncol; 2009 Jan; 27(1):158-9; author reply 159. PubMed ID: 19047277
[No Abstract] [Full Text] [Related]
18. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with
Yao YM; Donoho GP; Iversen PW; Zhang Y; Van Horn RD; Forest A; Novosiadly RD; Webster YW; Ebert P; Bray S; Ting JC; Aggarwal A; Henry JR; Tiu RV; Plowman GD; Peng SB
Clin Cancer Res; 2017 Sep; 23(18):5547-5560. PubMed ID: 28611205
[No Abstract] [Full Text] [Related]
19. BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
Qiu J; Compagnone M; Laibe S; Lagarde A; Goncalves A; Turrini O; Xerri L; Monges G; Olschwang S
Cancer Genomics Proteomics; 2011; 8(1):15-8. PubMed ID: 21289333
[TBL] [Abstract][Full Text] [Related]
20. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
Korphaisarn K; Kopetz S
Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
